期刊
THERANOSTICS
卷 11, 期 13, 页码 6334-6354出版社
IVYSPRING INT PUBL
DOI: 10.7150/thno.59342
关键词
co-delivery; dual-drug; multifunctional nanoplatform; multidrug resistance; cancer therapy
资金
- National Natural Science Foundation of China [51703189]
- Sichuan Science and Technology Program [2019YJ0245, 2020YFH0052]
- Fundamental Research Funds for the Central Universities [2682019CX76, 2682020ZT94]
- Key Project of Sichuan Science and Technology Innovation Engineering [2019129]
The primary cause of chemotherapy failure is cancer multidrug resistance (MDR), leading to recurrence and metastasis of cancer. Dual-therapeutic combination using multifunctional nanoplatforms is gaining attention for overcoming resistant cancers. Smart co-delivery nanocarriers can improve drug properties, enhance therapeutic efficacy, and even overcome drug resistance.
Clinically, the primary cause of chemotherapy failure belongs to the occurrence of cancer multidrug resistance (MDR), which directly leads to the recurrence and metastasis of cancer along with high mortality. More and more attention has been paid to multifunctional nanoplatform-based dual-therapeutic combination to eliminate resistant cancers. In addition to helping both cargoes improve hydrophobicity and pharmacokinetic properties, increase bioavailability, release on demand and enhance therapeutic efficacy with low toxic effects, these smart co-delivery nanocarriers can even overcome drug resistance. Here, this review will not only present different types of co-delivery nanocarriers, but also summarize targeted and stimuli-responsive combination nanomedicines. Furthermore, we will focus on the recent progress in the co-delivery of dual-drug using such intelligent nanocarriers for surmounting cancer MDR. Whereas it remains to be seriously considered that there are some knotty issues in the fight against MDR of cancers via using co-delivery nanoplatforms, including limited intratumoral retention, the possible changes of combinatorial ratio under complex biological environments, drug release sequence from the nanocarriers, and subsequent free-drug resistance after detachment from the nanocarriers. It is hoped that, with the advantage of continuously developing nanomaterials, two personalized therapeutic agents in combination can be better exploited to achieve the goal of cooperatively combating cancer MDR, thus advancing the time to clinical transformation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据